Ashraf Mikhail

Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

Iain C. Macdougall, Andreas J. Bircher, Kai‐Uwe Eckardt et al. · Kidney International · 2016 · 468 citations · Full text

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Increased Expression of Erythropoiesis Inhibiting Cytokines (IFN-γ, TNF-α, IL-10, and IL-13) by T Cells in Patients Exhibiting a Poor Response to Erythropoietin Therapy

Angela C. Cooper, Ashraf Mikhail, Mark W. Lethbridge et al. · Journal of the American Society of Nephrology · 2003 · 136 citations

Diagnosis and Management of Iron Deficiency in CKD: A Summary of the NICE Guideline Recommendations and Their Rationale

Laura E. Ratcliffe, Wayne Thomas, Jessica Glen et al. · American Journal of Kidney Diseases · 2016 · 124 citations

Anemia, Nutrition, Renal Function +14